EUVIMEDEUVIMED entdecken
Crossref

A biomimetic nanoplatform mediates hypoxia-adenosine axis disruption and PD-L1 knockout for enhanced MRI-guided chemodynamic-immunotherapy

Mengyu Sun, Cheng Ni, Aiyu Li, Junjie Liu, Honghua Guo, Fanyong Xu, Kangan Li, Xueyan Cao, Xiangyang Shi, Rui Guo

Acta Biomaterialia · 2025

DOI: 10.1016/j.actbio.2025.06.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Mengyu Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regener…. Hauptthemen laut MEDLINE: Immunotherapy, B7-H1 Antigen, Nanoparticles, Magnetic Resonance Imaging. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant melanoma is an extremely aggressive and fatal form of skin cancer due to the limited efficacy of conventional therapies. While immune checkpoint blockade therapy and chemodynamic therapy (CDT) have emerged as promising strategies for melanoma treatment, their effectiveness is compromised by the immunosuppressive and complex tumor microenvironment (TME). Here, cancer cell membrane-camouflaged nanoplatforms (PPMC@CM) were developed to co-deliver the CRISPR/Cas9-PD-L1 system and manganese dioxide nanoparticles (MnO2 NPs) for magnetic resonance imaging (MRI)-guided CDT and enhanced immunotherapy. The formed PPMC@CM could efficiently accumulate at tumor sites by homologous targeting, generate O2 to relieve hypoxia, and deplete glutathione (GSH) to enhance Mn2+-mediated Fenton-like reactions for enhanced CDT. Meanwhile, CRISPR/Cas9-mediated PD-L1 knockout effectively suppressed the PD-L1 expression, while hypoxia relief attenuated the immunosuppressive hypoxia-CD39/CD73-adenosine (ADO) pathway, thereby boosting the PD-L1-mediated immunotherapy. In vivo experimental results demonstrated that PPMC@CM nanoplatform could efficiently inhibit the growth and metastasis of melanoma by enhanced CDT and amplified immunotherapy, and provide targeted MRI of tumors. This work presents a novelty strategy to design biomimetic theranostic nanoplatform for melanoma by the combination of CDT and improved immunotherapy with CRISPR/Cas9-PD-L1 system and hypoxia-ADO axis inhibition. STATEMENT OF SIGNIFICANCE: Malignant melanoma is a highly aggressive and treatment-refractory skin cancer, where conventional therapies exhibit limited efficacy and immune checkpoint blockade (ICB) is often compromised by the immunosuppressive tumor microenvironment (TME). To address these challenges, we developed a biomimetic nanoplatform (PPMC@CM) to codeliver MnO₂ nanoparticles and the CRISPR/Cas9-PD-L1 gene-editing system for MRI-guided chemodynamic therapy and enhanced immunotherapy. The PPMC@CM nanoplatform could efficiently accumulate at tumor sites by homologous targeting and relieve hypoxia to suppress the hypoxia-CD39/CD73-adenosine immunosuppressive axis. Additionally, the CRISPR/Cas9-mediated PD-L1 knockout significantly suppresses PD-L1 expression, thereby boosting ICB efficacy. Moreover, PPMC@CM could deplete glutathione in the TME to amplify Mn2+-mediated Fenton-like reactions for enhanced chemodynamic therapy. This research represents a promising theranostic nanoplatform for melanoma by combining chemodynamic therapy and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyB7-H1 AntigenNanoparticlesMagnetic Resonance ImagingAdenosineBiomimetic MaterialsGene Knockout TechniquesAnimalsMiceCell Line, TumorManganese CompoundsHumansCRISPR-Cas SystemsOxidesTumor MicroenvironmentMelanoma, ExperimentalBiomimetics

Stichwörter der Autor:innen

CRISPR/Cas9 systemChemodynamic therapyHypoxia-adenosine axisImmunotherapyMRI

Substanzen

B7-H1 AntigenManganese CompoundsAdenosinemanganese dioxideOxides

Autor:innen und Institutionen

  • State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering,…
  • Department of Radiology, Shanghai Songjiang District Central Hospital, Shanghai 201620, China.
  • Mini-invasive Interventional Therapy Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Sun, M., Ni, C., Li, A., Liu, J., Guo, H., Xu, F., Li, K., Cao, X., Shi, X., & Guo, R. (2025). A biomimetic nanoplatform mediates hypoxia-adenosine axis disruption and PD-L1 knockout for enhanced MRI-guided chemodynamic-immunotherapy. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.06.021

Vancouver

Sun M, Ni C, Li A, Liu J, Guo H, Xu F, et al. A biomimetic nanoplatform mediates hypoxia-adenosine axis disruption and PD-L1 knockout for enhanced MRI-guided chemodynamic-immunotherapy. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.06.021

BibTeX
@article{Sun2025,
  author = {Sun, Mengyu and Ni, Cheng and Li, Aiyu and Liu, Junjie and Guo, Honghua and Xu, Fanyong and Li, Kangan and Cao, Xueyan and Shi, Xiangyang and Guo, Rui},
  title = {A biomimetic nanoplatform mediates hypoxia-adenosine axis disruption and PD-L1 knockout for enhanced MRI-guided chemodynamic-immunotherapy},
  journal = {Acta Biomaterialia},
  year = {2025},
  doi = {10.1016/j.actbio.2025.06.021}
}
Kostenlos starten →